Download Free Sample Report

Bone Metastasis Therapeutics Market, Global Outlook and Forecast 2023-2029

Bone Metastasis Therapeutics Market, Global Outlook and Forecast 2023-2029

  • Published on : 06 June 2023
  • Pages :65
  • Report Code:SMR-7704776

Download Report PDF Instantly

Leave This Empty:

Secure

Report overview

Bone metastasis is the third most common condition in metastatic cancers and occurs in 60-65% of patients with metastatic cancers. The spine is the most common site of bone metastasis. Other common sites include ribs, skull, pelvis (hip bone), femur (leg bone) and humerus (arm bone). Bone metastatic cancers are rarely able to be cured, and treatment of bone metastasis involves medications to shrink, stop or slow down the growth of the tumor. Treatment options available for bone metastasis are symptomatic treatments which are meant for pain control, treatment, and prevention of fractures, improvement in functional disability, etc. Randomized trials on metastatic patients by UBM Medica, LLC showed that 45-75% patients develop functional disability every 3-4 months, 10-15% patients develop hypercalcemia and 10-20% patients develop long bone fractures.?
This report aims to provide a comprehensive presentation of the global market for Bone Metastasis Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Bone Metastasis Therapeutics. This report contains market size and forecasts of Bone Metastasis Therapeutics in global, including the following market information:
Global Bone Metastasis Therapeutics Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Bone Metastasis Therapeutics market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Treatment of bone metastasis is the interdisciplinary field involving pain management, orthopedics, and other medical specialties. Primary factors driving the growth of bone metastasis therapeutics market are the global increase in cancer prevalence and delayed diagnosis of cancer in low-income countries. According to University of Texas Southwestern Medical Center Dallas, over 600,000 of bone metastasis are diagnosed in the U.S. every year. Rapid innovation in the field of personalized medicine and identification of new therapeutic targets for bone metastasis presents a huge opportunity to manufacturers of targeted therapy agents. A large number of treatment methods are still under investigation. However, heterogeneous nature of cancer and high development cost of neoplastic agents are the factors limiting the growth of global bone metastasis therapeutics market.
We surveyed the Bone Metastasis Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Bone Metastasis Therapeutics Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Bone Metastasis Therapeutics Market Segment Percentages, by Type, 2022 (%)
Drug Treatment
Tumor Ablation Therapy
Surgery
Global Bone Metastasis Therapeutics Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Bone Metastasis Therapeutics Market Segment Percentages, by Application, 2022 (%)
Hospitals
Cancer Rehabilitation Centers
Specialty Clinics
Ambulatory Surgical Centers
Global Bone Metastasis Therapeutics Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Bone Metastasis Therapeutics Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Bone Metastasis Therapeutics revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Bone Metastasis Therapeutics revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
F. Hoffmann-La Roche
Bayer
Merck
Pfizer
Novartis
Amgen
Pharmalucence
Fresenius Kabi
Omega Laboratories
Eli Lilly
Outline of Major Chapters:
Chapter 1: Introduces the definition of Bone Metastasis Therapeutics, market overview.
Chapter 2: Global Bone Metastasis Therapeutics market size in revenue.
Chapter 3: Detailed analysis of Bone Metastasis Therapeutics company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Bone Metastasis Therapeutics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.